Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Leqvio (inclisiran) is approved by MHLW for familial and non-familial hypercholesterolemia and for patients who are at a high risk of developing cardiovascular events – Novartis

Written by | 1 Oct 2023

Leqvio (inclisiran), became the first siRNA therapy for dyslipidemia approved in Japan. The drug was approved for familial and non-familial hypercholesterolemia and is intended for patients who are… read more.

China’s NMPA approves Sintbilo for primary hypercholesterolemia and dyslipidemia – Innovent Biologics

Written by | 28 Aug 2023

Innovent Biologics announces that China’s National Medical Products Administration (NMPA) has approved Sintbilo (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolemia (including… read more.

Bempedoic acid lowers cardiovascular risks in statin intolerant patients

Written by | 29 Jun 2023

Researchers report that treatment with bempedoic acid in high-risk primary prevention patients who cannot tolerate recommended doses of statins reduces major adverse cardiovascular events. The findings were published… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.